Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review

BACKGROUND: androgen receptor variant 7 (AR-V7) has been suggested as potential marker for treatment selection in men with metastatic castration-resistant prostate cancer (mCRPC). The aim of the present review is to critically analyze: frequency of the AR-V7 expression in mCRPC cases—impact of AR-V7...

Descripción completa

Detalles Bibliográficos
Autores principales: Sciarra, Alessandro, Gentilucci, Alessandro, Silvestri, Ida, Salciccia, Stefano, Cattarino, Susanna, Scarpa, Susanna, Gatto, Antonio, Frantellizzi, Viviana, Von Heland, Magnus, Ricciuti, Gian Piero, Del Giudice, Francesco, Maggi, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531263/
https://www.ncbi.nlm.nih.gov/pubmed/31083254
http://dx.doi.org/10.1097/MD.0000000000015608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531263/
https://www.ncbi.nlm.nih.gov/pubmed/31083254
http://dx.doi.org/10.1097/MD.0000000000015608

Ejemplares similares